Development of a decision-making biomarker for CRTH2 antagonism in clinical studies

@article{Strasser2015DevelopmentOA,
  title={Development of a decision-making biomarker for CRTH2 antagonism in clinical studies},
  author={D. Strasser and H. Farine and M. Holdener and J. Zisowsky and Ren{\'e} Roscher and Julie Hoerner and M. G{\'e}hin and P. Sidharta and J. Dingemanse and P. Groenen},
  journal={New Horizons in Translational Medicine},
  year={2015},
  volume={2},
  pages={118-125}
}
  • D. Strasser, H. Farine, +7 authors P. Groenen
  • Published 2015
  • Biology
  • New Horizons in Translational Medicine
  • Abstract Biomarkers have shown to improve success rates in the development of novel drugs, providing essential information in the early phases of clinical development for decision-making. Chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) is pursued as a drug target for a number of inflammatory diseases. CRTH2 antagonists block the activation and migration of key inflammatory cells such as eosinophils, basophils, and Th2 cells. The mechanism of action of CRTH2… CONTINUE READING
    7 Citations

    Figures and Tables from this paper

    Pharmacokinetic/Pharmacodynamic Modelling of Receptor Internalization with CRTH2 Antagonists to Optimize Dose Selection
    • 6
    CYP2C9 involvement in ACT‐453859 metabolism
    Impact of pharmacokinetic‐pharmacodynamic modelling in early clinical drug development
    • J. Dingemanse, Andreas Krause
    • Medicine
    • European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
    • 2017
    • 2

    References

    SHOWING 1-10 OF 43 REFERENCES
    Novel CRTH2 antagonists: a review of patents from 2006 to 2009
    • 48
    Association of a new-type prostaglandin D2 receptor CRTH2 with circulating T helper 2 cells in patients with atopic dermatitis.
    • 88
    A novel CRTH2 antagonist: Single‐ and multiple‐dose tolerability, pharmacokinetics, and pharmacodynamics of ACT‐453859 in healthy subjects
    • 15
    Selective expression of a novel surface molecule by human Th2 cells in vivo.
    • 376
    PGD2 metabolism in plasma: kinetics and relationship with bioactivity on DP1 and CRTH2 receptors.
    • 60
    Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis.
    • 47
    Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases
    • 260
    Anti‐eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis
    • 156